FindTrial
Sign In

Targeted Systemic Therapy

DRUG2 trials

Sponsors

David Palma, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions

Esophageal CancerEsophageal CarcinomaGastric (Cardia, Body) CancerGastric (Stomach) CancerGastric AdenocarcinomaGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaMetastatic Tumor

Phase 2

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Not yet recruitingNCT07000253
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Esophageal Cancer, Esophageal Carcinoma, Gastric Adenocarcinoma +3
Start: 2026-01-31End: 2034-01-31Target: 290Updated: 2025-06-02

Phase 3

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
RecruitingNCT05717166
David PalmaMetastatic Tumor
Start: 2023-10-06End: 2029-04-30Target: 180Updated: 2025-12-31

Related Papers

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol
BMC Palliative Care2024-09-0710 citations